On December 3, 2020, EOFlow announces that it has received the final report on the post-market clinical study on EOPatch wearable insulin pump system, conducted in Korea over the summer this year.  The study was conducted on 9 patients over a month's time and it showed significant improvement on TIR (Time in Range), with subject patients staying within the target blood glucose range (70~180mg/dL) much longer, and having significantly less incidents of severe hypoglycemic events (<54mg/dL).  7 patients out of 9 had expressed their satisfaction with the ease of use, and 8 out of 9 had expressed satisfaction on the aspect of life quality improvement.  This was the very first official clinical study conducted with EOFlow's EOPatch wearable insulin pump system.